Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, describes the Phase Ib/II trial (NCT02501096) exploring lenvatinib plus pembrolizumab in patients with selected solid tumors, including advanced refractory endometrial cancer. Results demonstrated an impressive overall survival among a subgroup of patients with microsatellite instability (MSI)–high tumors and mismatch repair (MMR) deficiency. Additionally, the first-in-human Phase I EVICTION (NCT04243499) dose escalation trial evaluating the novel combination of ICT01 plus pembrolizumab in patients with advanced cancer is outlined. In this Phase I trial, although predominantly stable disease and stable responses were observed, there was a case of PD-1 refractory melanoma with intercranial metastasis that demonstrated complete regression. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
